Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs Viatris Inc — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $62 (market cap $78.85B), while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 4.2× Viatris Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays the higher dividend (3.24%). Which is the better fit depends on your goals.
| MDLZ | VTRS | |
|---|---|---|
Market Cap | $78.85B | $18.69B |
Sector | Consumer Staples | Health |
52-Week High | $64.99 | $17.86 |
52-Week Low | $51.51 | $9.49 |
Enterprise Value | $99.19B | $30.80B |
Dividend Yield | 3.24% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $61.71, up 0.28% on the day, reflecting steady momentum after a series of earnings beats. The stock exhibits a bullish technical trend, supported by strong moving averages. Fundamentally, the company reported Q2 2026 EPS of $0.73, exceeding estimates, and raised its organic sales outlook for 2026. Revenue growth is solid, though net income margin compression from 2023 peaks remains a watch point. Analyst sentiment is overwhelmingly positive, with a consensus price target of $70.50 implying significant upside.
The outlook for MDLZ is favorable, driven by pricing power, volume growth in emerging markets, and a robust brand portfolio. Key opportunities include market share gains and consistent dividend payments. Primary risks involve exposure to international economic volatility, inflationary cost pressures, and intense competition in the snack food industry. The stock presents a compelling case for growth-oriented investors seeking stability in consumer staples.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
